» Articles » PMID: 30229283

[Crohn's Disease-associated Colorectal Carcinogenesis : TP53 Mutations and Copy Number Gains of Chromosome Arm 5p As (early) Markers of Tumor Progression]

Overview
Journal Pathologe
Specialty Pathology
Date 2018 Sep 20
PMID 30229283
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with inflammatory bowel diseases, i. e., ulcerative colitis and Crohn's disease (CD), face an increased risk of developing colorectal cancer (CRC). Evidence, mainly from ulcerative colitis, suggests that TP53 mutations represent an initial step in the progression from inflamed colonic epithelium to CRC.

Objectives: In this study, we aimed to analyze the genetic events that define CD-CRCs, in particular the dynamics of their development from histologically undetectable precursor lesions to invasive disease.

Materials And Methods: We analyzed 73 tissue samples from 28 patients with CD-CRC, including precursor lesions by next generation sequencing (563 gene panel) and array-based comparative genomic hybridization. The results were compared with our own data and the Cancer Genome Atlas data on sporadic CRC.

Results: The gain of 5p was significantly more prevalent in CD-CRCs than in sporadic CRCs, despite an overall similar chromosomal aberration pattern. CD-CRCs had a distinct mutation signature with TP53 being the most frequently mutated gene in CD-CRCs. TP53 mutations and copy number alterations were early events in CD progression and could sometimes already be detected in non-dysplastic colonic mucosa, indicating occult tumor evolution.

Conclusions: Molecular profiling of CD-CRCs and precursor lesions revealed an inflammation-associated landscape of genome alterations: gains of 5p and TP53 mutations occurred early in tumor development. Detection of these aberrations in precursor lesions may help predict disease progression and distinguishes CD-associated from sporadic colorectal neoplasia.

Citing Articles

Machine learning‑based radiomics models accurately predict Crohn's disease‑related anorectal cancer.

Horio Y, Ikeda J, Matsumoto K, Okada S, Nagano K, Kusunoki K Oncol Lett. 2024; 28(3):421.

PMID: 39035049 PMC: 11258598. DOI: 10.3892/ol.2024.14553.


Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Huai Hua San Against Ulcerative Colitis.

Liu J, Liu J, Tong X, Peng W, Wei S, Sun T Drug Des Devel Ther. 2021; 15:3255-3276.

PMID: 34349502 PMC: 8326529. DOI: 10.2147/DDDT.S319786.


[Colorectal tumor evolution in inflammatory bowel disease : Dynamics of genomic alterations and potential molecular markers to predict malignant progression].

Hirsch D Pathologe. 2019; 40(Suppl 3):232-238.

PMID: 31811372 DOI: 10.1007/s00292-019-00709-3.

References
1.
Sato A, Machinami R . p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol Int. 1999; 49(10):858-68. DOI: 10.1046/j.1440-1827.1999.00965.x. View

2.
Noffsinger A, Belli J, Miller M, Fenoglio-Preiser C . A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene. Histopathology. 2001; 39(5):482-92. DOI: 10.1046/j.1365-2559.2001.01274.x. View

3.
Richter H, Slezak P, Walch A, Werner M, Braselmann H, Jaramillo E . Distinct chromosomal imbalances in nonpolypoid and polypoid colorectal adenomas indicate different genetic pathways in the development of colorectal neoplasms. Am J Pathol. 2003; 163(1):287-94. PMC: 1868156. DOI: 10.1016/S0002-9440(10)63652-8. View

4.
Garnis C, Davies J, Buys T, Tsao M, MacAulay C, Lam S . Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene. 2005; 24(30):4806-12. DOI: 10.1038/sj.onc.1208643. View

5.
van Dieren J, Wink J, Vissers K, van Marion R, Hoogmans M, Dinjens W . Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. Diagn Mol Pathol. 2006; 15(4):216-22. DOI: 10.1097/01.pdm.0000213470.92925.18. View